XML 151 R128.htm IDEA: XBRL DOCUMENT v3.25.0.1
Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities      
Net income (loss) $ 1,091.1 $ (496.7) $ 1,284.7
Adjustments to reconcile net income (loss) to net cash flows from operating activities:      
Depreciation and amortization 184.1 180.6 147.4
Equity-based compensation 467.9 249.1 154.0
Non-cash performance allocations and incentive fees (359.3) 1,572.8 393.6
Non-cash principal investment income (209.6) (123.9) (553.4)
Other non-cash amounts 1.8 23.8 (10.3)
Purchases of investments (385.9) (301.2) (629.9)
Proceeds from the sale of investments 498.0 472.2 474.9
Payments of contingent consideration (4.1) (68.6) (5.7)
Changes in deferred taxes, net 91.2 (368.7) (73.2)
Change in due from affiliates and other receivables (27.6) (33.4) (82.5)
Change in deposits and other 8.5 6.3 (11.8)
Change in accounts payable, accrued expenses and other liabilities 58.8 (33.2) (14.3)
Change in accrued compensation and benefits (37.1) 10.6 (135.4)
Change in due to affiliates (11.7) (14.5) 1.7
Change in lease right-of-use asset and lease liability (8.1) (10.8) (8.8)
Change in deferred revenue (0.2) 15.3 4.5
Net cash provided by (used in) operating activities (759.5) 204.9 (379.3)
Cash flows from investing activities      
Purchases of corporate treasury investments (5.0) (187.3) (69.6)
Proceeds from corporate treasury investments 5.1 210.3 50.0
Purchases of fixed assets, net (77.7) (66.6) (40.6)
Purchase of Abingworth, net of cash acquired 0.0 0.0 (150.2)
Purchase of CBAM intangibles and investments 0.0 0.0 (618.4)
Net cash used in investing activities (77.6) (43.6) (828.8)
Cash flows from financing activities      
Borrowings under credit facilities 10.4 0.0 0.0
Repayments under credit facilities (10.4) 0.0 0.0
Proceeds from CLO borrowings, net of financing costs 0.7 12.0 73.2
Payments on CLO borrowings (120.5) (17.2) (16.7)
Dividends to common stockholders (503.0) (497.7) (443.6)
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8) (68.8)
Contributions from non-controlling interest holders 319.5 177.0 391.2
Distributions to non-controlling interest holders (178.4) (139.7) (216.8)
Common shares issued for performance allocations 0.0 0.0 38.9
Common shares repurchased and net share settlement of equity awards (554.6) (203.5) (185.6)
Change in due to/from affiliates financing activities (37.1) (62.3) (81.2)
Net cash provided by (used in) financing activities 682.8 (99.6) 114.8
Effect of foreign exchange rate changes (21.3) 18.9 (20.3)
Increase (decrease) in cash, cash equivalents and restricted cash (175.6) 80.6 (1,113.6)
Cash, cash equivalents and restricted cash, beginning of period 1,442.1 1,361.5 2,475.1
Cash, cash equivalents and restricted cash, end of period 1,266.5 1,442.1 1,361.5
Reconciliation of cash, cash equivalents and restricted cash, end of period:      
Cash and cash equivalents 1,266.0 1,440.3 1,360.7
Restricted cash 0.5 1.8 0.8
Total cash, cash equivalents and restricted cash, end of period 1,266.5 1,442.1 1,361.5
Cash and cash equivalents held at Consolidated Funds 830.4 346.0 209.0
Consolidated Operating Entities      
Cash flows from operating activities      
Net income (loss) 1,082.4 (579.3) 1,248.6
Adjustments to reconcile net income (loss) to net cash flows from operating activities:      
Depreciation and amortization 184.1 180.6 147.4
Equity-based compensation 467.9 249.1 154.0
Non-cash performance allocations and incentive fees (360.6) 1,569.2 387.5
Non-cash principal investment income (207.0) (130.7) (501.5)
Other non-cash amounts 1.8 23.8 (10.3)
Purchases of investments (886.7) (345.8) (737.7)
Proceeds from the sale of investments 737.5 485.9 498.0
Payments of contingent consideration (4.1) (68.6) (5.7)
Changes in deferred taxes, net 91.2 (368.7) (73.2)
Change in due from affiliates and other receivables (27.8) (33.5) (82.3)
Change in deposits and other 8.5 6.3 (11.8)
Change in accounts payable, accrued expenses and other liabilities 58.8 (33.2) (14.3)
Change in accrued compensation and benefits (37.1) 10.6 (135.4)
Change in due to affiliates (11.7) (14.5) 1.7
Change in lease right-of-use asset and lease liability (8.1) (10.8) (8.8)
Change in deferred revenue (0.2) 15.3 4.5
Net cash provided by (used in) operating activities 1,088.9 955.7 860.7
Cash flows from investing activities      
Purchases of corporate treasury investments (5.0) (187.3) (69.6)
Proceeds from corporate treasury investments 5.1 210.3 50.0
Purchases of fixed assets, net (77.7) (66.6) (40.6)
Purchase of Abingworth, net of cash acquired 0.0 0.0 (150.2)
Purchase of CBAM intangibles and investments 0.0 0.0 (618.4)
Net cash used in investing activities (77.6) (43.6) (828.8)
Cash flows from financing activities      
Borrowings under credit facilities 10.4 0.0 0.0
Repayments under credit facilities (10.4) 0.0 0.0
Proceeds from CLO borrowings, net of financing costs 0.7 12.0 73.2
Payments on CLO borrowings (120.5) (17.2) (16.7)
Dividends to common stockholders (503.0) (497.7) (443.6)
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8) (68.8)
Contributions from non-controlling interest holders 229.5 11.8 9.2
Distributions to non-controlling interest holders (131.0) (64.0) (78.7)
Common shares issued for performance allocations 0.0 0.0 38.9
Common shares repurchased and net share settlement of equity awards (554.6) (203.5) (185.6)
Change in due to/from affiliates financing activities (24.4) (16.2) (456.2)
Net cash provided by (used in) financing activities (1,172.1) (843.6) (1,128.3)
Effect of foreign exchange rate changes (14.8) 12.1 (17.2)
Increase (decrease) in cash, cash equivalents and restricted cash (175.6) 80.6 (1,113.6)
Cash, cash equivalents and restricted cash, beginning of period 1,442.1 1,361.5 2,475.1
Cash, cash equivalents and restricted cash, end of period 1,266.5 1,442.1 1,361.5
Supplemental cash disclosures      
Issuance of common shares related to the acquisition of CBAM and Abingworth 0.0 0.0 219.5
Reconciliation of cash, cash equivalents and restricted cash, end of period:      
Cash and cash equivalents 1,266.0 1,440.3 1,360.7
Restricted cash 0.5 1.8 0.8
Total cash, cash equivalents and restricted cash, end of period 1,266.5 1,442.1 1,361.5
Cash and cash equivalents held at Consolidated Funds $ 830.4 $ 346.0 $ 209.0